Zhejiang Int'l Group Co Documents
Documents
0
Ticker
000411.SZ
ISIN
CNE0000008D9
Zhejiang Int'l Group Co SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
Zhejiang Int'l Group Co Documents 2026
This page contains all official documents and SEC filings for Zhejiang Int'l Group Co stock (000411.SZ, ISIN: CNE0000008D9). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of Zhejiang Int'l Group Co's regulatory filings.
Zhejiang Int'l Group Co Stock analysis
Zhejiang Int'l Group Co Zhejiang Int'l Group Co., Ltd. generates revenue by wholesaling and retailing pharmaceuticals and medical devices. The company buys products from pharmaceutical manufacturers or suppliers and distributes them to distributors, medical institutions, and pharmacies. It also sells directly to consumers through retail terminals. The firm operates exclusively within Mainland China, serving a broad customer base across the healthcare sector. The business model relies on purchasing products from manufacturers or suppliers, then reselling them through wholesale channels to medical institutions and pharmacies, or via retail terminals to end consumers. This dual-channel approach allows the company to reach both institutional and individual customers without direct manufacturing involvement. Mainland China represents the sole market for all its operations. Zhejiang Int'l Group Co., Ltd. focuses on pharmaceutical and medical device distribution, targeting distributors, medical institutions, and pharmacies as key wholesale clients. Retail sales are directed toward consumers through its own retail terminals. The company does not engage in manufacturing, instead acting as a middleman between producers and end users within the Chinese healthcare market.